Tian Zhang, MD, discusses data from the randomized phase III IMvigor130 trial, which compared the safety and efficacy of atezolizumab in combination with platinum-based chemotherapy, atezolizumab monotherapy, and chemotherapy alone, in the frontline treatment of patients with metastatic urothelial cancer.
Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.
Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the long-term data from the phase II ABC study , in which investigators are comparing the efficacy of nivolumab in combination with ipilimumab versus single-agent nivolumab in patients with melanoma brain metastases.
Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.
Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.
Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.
Anuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.
Eileen O'Reilly, MD, discusses the phase II NEOLAP study which showed that more patients with locally advanced pancreatic cancer were able to undergo surgical resection following induction chemotherapy with gemcitabine and nab-paclitaxel or sequential FOLFIRINOX.
Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Feinberg School of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the results of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).
Paul Kelly Marcom, MD, discusses the use of liquid biopsies in breast cancer treatment.
Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.
Nirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.
Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the results of a phase II trial evaluating the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.
Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.
Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.
John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.
Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.
Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.
Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.
Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.
Laura L. Holman, MD, discusses screening options for ovarian cancer.
R. Lor Randall, MD, FACS, discusses using pexidartinib to treat tenosynovial giant cell tumor.
Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.
Massimo Cristofanilli, MD, professor of medicine, Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses data with lasofoxifene in women with ESR1-mutant breast cancer.
Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.
William L. Dahut, MD, discusses multiparametric magnetic resonance imaging as an alternative screening technique to prostate-specific antigen testing in prostate cancer.
Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.
Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.
Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.
Leonard G. Gomella, MD, discusses the challenges of genetic testing in prostate cancer.
